Live feed15:15:00·1977dPRReleasevia QuantisnowBlueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid CancerByQuantisnow·Wall Street's wire, on your screen.BPMC· Blueprint Medicines CorporationHealth CareOriginal source
